Researcher
Annick Moens
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Aug 2017 → 11 Oct 2021
Projects
1 - 1 of 1
- LONG-TERM SEQUENTIAL USE OF BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE: HARMLESS OR HAZARDOUS?From1 Aug 2017 → 24 Sep 2021Funding: FWO fellowships
Publications
1 - 10 of 10
- LONG-TERM SAFETY OF THE (SEQUENTIAL) USE OF BIOLOGICAL THERAPIES IN INFLAMMATORY BOWEL DISEASES(2021)
Authors: Annick Moens, Marc Ferrante, Séverine Vermeire
- Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding(2020)
Authors: Annick Moens, Marc Ferrante
Pages: 27 - 42Number of pages: 16 - Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center(2020)
Authors: Annick Moens, Gert Van Assche, Séverine Vermeire, Ann Gils, Marc Ferrante
Pages: 628 - 634Number of pages: 7 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2020)
Authors: Annick Moens, C Janneke van der Woude, Mette Julsgaard, Evelien Humblet, Juliette Sheridan, Daniel C Baumgart, Cyrielle Gilletta De Saint-Joseph, Stephane Nancey, Jean-Francois Rahier, Peter Bossuyt, et al.
Pages: 129 - 138Number of pages: 10 - Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study(2019)
Authors: Annick Moens, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pages: 129 - 138Number of pages: 10 - Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades(2019)
Authors: Annick Moens, Bram Verstockt, Kathleen Machiels, Peter Bossuyt, Katrien Lagrou, Gert Van Assche, Séverine Vermeire, Marc Ferrante
Pages: 668 - 673Number of pages: 6 - OUTCOMES OF PREGNANCY IN IBD PATIETNS TREATED WITH VEDOLIZUMAB, ANTI-TNF OR CONVENTIONAL THERAPY(2019)
Authors: Annick Moens, Christien Janneke Van der Woude, Mette Julsgaard, Shaji Sebastian, Naila Arebi, Mohannad Alzinaty, Evelien Humblet, Klaartje Kok, Juliette Sheridan, Cyrielle Gilletta, et al.
Pages: S633 - S633Number of pages: 1 - Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab(2019)
Authors: Annick Moens, Karen van Hoeve, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
Pages: 12 - 18Number of pages: 7 - CLOSTRIDIUM DIFFICILE INFECTIONS IN IBD: EPIDEMIOLOGY OVER TWO DECADES(2018)
Authors: Annick Moens, Bram Verstockt, Kathleen Machiels, Peter Bossuyt, Ann Verdonck, Katrien Lagrou, Séverine Vermeire, Marc Ferrante
Pages: S421 - S421Number of pages: 1 - Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy(2017)
Authors: Marc Ferrante, Anthony de Buck van Overstraeten, Annick Moens, Gert Van Assche, Albert Wolthuis, Séverine Vermeire, André D'Hoore
Pages: 1353 - 1361